Literature DB >> 17240090

Bone mineral density in breast cancer patients with positive estrogen receptor tumor status.

Tsutomu Douchi1, Yukie Yonehara, Shoichiro Kosha, Ichiro Iwamoto, Yoshiaki Rai, Yoshiatsu Sagara, Yoshihisa Umekita.   

Abstract

AIM: The aim was to investigate bone mineral density (BMD) in breast cancer patients with positive estrogen receptor (ER) tumor status.
METHODS: The participants were 110 postmenopausal breast cancer patients with positive estrogen receptor (ER+) tumor status. Two hundred and sixty-one age-matched, healthy postmenopausal women, all of whom were selected from our pooled data, served as controls. Age, age at menopause, years since menopause (YSM), height, weight, and body mass index (BMI, wt/ht(2)) were recorded. Lumbar spine (L2-4) BMD and Z-score were assessed by dual-energy X-ray absorptiometry.
RESULTS: Bone mineral density in breast cancer patients was significantly higher than that in controls (0.89+/-0.12 g/cm(2) versus 0.84+/-0.16 g/cm(2), P<0.01). The Z-score in breast cancer patients was also higher than that in controls (110+/-13.6% versus 100+/-9.8%, P<0.001). Higher BMD and Z-score in breast cancer patients remained significant after adjusting for age, YSM, and BMI (P<0.05).
CONCLUSIONS: Postmenopausal breast cancer patients with positive ER tumor status have higher BMD. Positive ER tumor status may be associated with higher cumulative exposure to estrogen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17240090     DOI: 10.1016/j.maturitas.2006.11.012

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  2 in total

1.  The Relationship between Bone Mineral Density and Estrogen Receptor Positivity in Patients with Breast Cancer.

Authors:  Zeynep Erdoğan İyigün; Kezban Nur Pilancı; Fatmagül Kuşku Çabuk; Serkan İlgün; Çetin Ordu; Tomris Duymaz; Gül Alço; Filiz Çelebi; Dauren Sarsenov; Filiz İzci; Alper Öztürk; Filiz Ağaçayak; Ülkühan İner Köksal; Fatma Aktepe; Yeşim Eralp; Vahit Özmen
Journal:  J Breast Health       Date:  2016-07-01

2.  Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells.

Authors:  Ana M Covaleda Sotoca; Hans van den Berg; Jacques Vervoort; Paul van der Saag; Anders Ström; Jan-Ake Gustafsson; Ivonne Rietjens; Albertinka J Murk
Journal:  Toxicol Sci       Date:  2008-07-21       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.